Cormorant Asset Management Increases Stake in Cabaletta Bio, Inc. to 9.03%

Cormorant Asset Management, LP and its managing member, Bihua Chen, have filed a Schedule 13G/A indicating a significant increase in their position in Cabaletta Bio, Inc. (CABA). As of March 31, 2026, the reporting persons beneficially own 10,500,000 shares of common stock, representing 9.03% of the class. This holding includes 5,000,000 shares issuable upon the exercise of warrants. The shares are held directly by various Cormorant Funds, with Cormorant Global Healthcare Master Fund, LP specifically identified as having the right to receive dividends or proceeds from more than 5% of the shares. The filing is an amendment to a previous 13G and reflects shared voting and dispositive power over the entire 10,500,000 share position. The acquisition was made in the ordinary course of business and not for the purpose of influencing control over the issuer. The ownership percentage is based on 111,322,671 shares outstanding as of March 19, 2026.